Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnLife for Prevention of Paclitaxel-Induced Neuropathy
NCT05695313Phase 2Recruiting
- Sponsor
- Centre Georges-François Leclerc
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Centre Georges-François Leclerc. Primary endpoint: Neuropathies graded by NCI-CTCAE version 5.0 at 3 months. Started Apr 2024; status: recruiting.
02
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05695313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695313.